Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 2/20 | 0.43 |
| ▸ | TERT | O14746 | 4/20 | 0.42 |
| ▸ | CYCS | P99999 | 3/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | STAT1 | P42224 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14181438 | 0.96 | STAT3 (0.46) | TOP1TERTCYCSENPP2STAT3 | |
| SCHEMBL249199 | 0.90 | TOP1 (0.50) | TOP1TERTCYCSENPP2STAT3 | |
| SCHEMBL31296593 | 0.90 | TOP1 (0.50) | TOP1TERTCYCSENPP2STAT3 | |
| SCHEMBL29556430 | 0.90 | TOP1 (0.50) | TOP1TERTCYCSENPP2STAT3 | |
| SCHEMBL8865323 | 0.89 | TERT (0.51) | TOP1TERTCYCSENPP2STAT3 | |
| SCHEMBL29648445 | 0.89 | TERT (0.51) | TOP1TERTCYCSENPP2STAT3 | |
| SCHEMBL30297908 | 0.89 | TERT (0.51) | TOP1TERTCYCSENPP2STAT3 | |
| Temoporfin SCHEMBL6422 | 0.86 | TOP1 (0.43) | TOP1TERTCYCSENPP2STAT3 | |
| SCHEMBL1640992 | 0.86 | TOP1 (0.54) | TOP1TERTCYCSENPP2STAT3 | |
| SCHEMBL29358555 | 0.85 | TOP1 (0.42) | TOP1TERTCYCSENPP2STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210236424-A1 | BINARY LIPID BILAYER-CONTAINING VESICLES COMPRISING EMBEDDED CYTOTOXIC AGENTS AND METHODS OF MAKING AND USING THE SAME | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-08-05 | — | — | US | claimed |
| US-20060040912-A1 | Compounds for pdt | BIOSCIENCE TECHNOLOGY INVESTMENT HOLDINGS LIMITED (MY) | 2006-02-23 | — | — | US | claimed |
| EP-1263761-B1 | COMPOUNDS FOR PDT | BIOLITEC PHARMA MARKETING LTD (MY) | 2004-12-01 | — | — | EP | claimed |
| EP-0337601-B1 | PORPHYRINS AND MEDICAMENTS FOR CANCER TREATMENT | SCOTIA HOLDINGS PLC (GB) | 1993-05-05 | — | — | EP | claimed |
| US-12364759-B2 | Polymer-particle light-cleavable carrier systems for photodynamic therapy | Westfälische Wilhelms-Universität Münster (DE) | 2025-07-22 | — | — | US | disclosed |
| US-12178907-B2 | Binary lipid bilayer-containing vesicles comprising embedded cytotoxic agents and methods of making and using the same | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-12-31 | — | — | US | disclosed |
| EP-4225759-A1 | TETRAPYRROLE-BASED COMPOUNDS AND THEIR FORMULATIONS FOR ANTI-MICROBIAL THERAPY | biolitec Unternehmensbeteiligungs II AG (AT) | 2023-08-16 | — | — | EP | disclosed |
| US-20220142922-A1 | LIPOSOMAL NANOCONSTRUCTS AND METHODS OF MAKING AND USING THE SAME | THE GENERAL HOSPITAL CORPORATION | 2022-05-12 | — | — | US | disclosed |
| WO-2022074014-A1 | TETRAPYRROLE-BASED COMPOUNDS AND THEIR FORMULATIONS FOR ANTI-MICROBIAL THERAPY | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2022-04-14 | — | — | WO | disclosed |
| US-20210236424-A1 | BINARY LIPID BILAYER-CONTAINING VESICLES COMPRISING EMBEDDED CYTOTOXIC AGENTS AND METHODS OF MAKING AND USING THE SAME | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-08-05 | — | — | US | disclosed |
| US-20180161272-A1 | LIPOSOMAL NANOCONSTRUCTS AND METHODS OF MAKING AND USING THE SAME | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2018-06-14 | — | — | US | disclosed |
| EP-3302436-A1 | LIPOSOMAL NANOCONSTRUCTS AND METHODS OF MAKING AND USING THE SAME | The General Hospital Corporation (US) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016191556-A1 | LIPOSOMAL NANOCONSTRUCTS AND METHODS OF MAKING AND USING THE SAME | THE GENERAL HOSPITAL CORPORATION (US) | 2016-12-01 | — | — | WO | disclosed |
| WO-2012076631-A1 | SYSTEM AND METHOD FOR INTERSTITIAL PHOTODYNAMIC LIGHT THERAPY IN COMBINATION WITH PHOTOSENSITIZERS | SPECTRACURE AB (SE) | 2012-06-14 | — | — | WO | disclosed |
| US-7375215-B2 | tetrakis(hydroxyphenyl)chlorin, bacteriochlorin or isobacteriochlorin, derivatised at one or more of the hydroxy groups by addition reaction with a diisocyanate, diisothiocyanate or isocyanate; photodynamic therapy of cancerous and other diseased tissues | BIOSCIENCE TECHNOLOGY INVESTMENT HOLDINGS LIMITED (MY) | 2008-05-20 | — | — | US | disclosed |
| US-20060040912-A1 | Compounds for pdt | BIOSCIENCE TECHNOLOGY INVESTMENT HOLDINGS LIMITED (MY) | 2006-02-23 | — | — | US | disclosed |
| EP-1263761-B1 | COMPOUNDS FOR PDT | BIOLITEC PHARMA MARKETING LTD (MY) | 2004-12-01 | — | — | EP | disclosed |
| EP-0337601-B1 | PORPHYRINS AND MEDICAMENTS FOR CANCER TREATMENT | SCOTIA HOLDINGS PLC (GB) | 1993-05-05 | — | — | EP | disclosed |
| US-5162519-A | Porphyrins and cancer treatment | EFAMOL HOLDINGS PLC (GB) | 1992-11-10 | — | — | US | disclosed |
| US-4992257-A | Dihydroporphyrins and method of treating tumors | EFAMOL HOLDINGS PLC (GB) | 1991-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12364759-B2 | Polymer-particle light-cleavable carrier systems for photodynamic therapy | PIN1, PPOX, CLTA | TOP1 1402/4885TERT 3389/4885CYCS 785/4885 |
| US-20060040912-A1 | Compounds for pdt | PPOX, DHPS, HMBS | TOP1 1475/4885TERT 669/4885CYCS 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.